On January 20, 2026, Abraham Ceesay, the Chief Executive Officer of Rapport Therapeutics, Inc. (NASDAQ:RAPP), proceeded with the sale of a combined 10,916 shares of the company's common stock, generating roughly $285,070 in proceeds. These transactions were divided into two parts, both carried out at weighted average prices just above $26 per share within a price range of $25.83 to $26.70.
In the initial sale, Ceesay disposed of 5,833 shares at a weighted average price of $26.1158, yielding about $152,320. Post-sale, his direct ownership stands at 562,080 shares, maintaining significant stake in the firm. The second transaction involved the sale of 5,083 shares held via The Dorothy Ceesay Irrevocable Trust. These shares were sold at a weighted average price of $26.1140, producing proceeds close to $132,750. Following this, the trust retains 25,812 shares under its possession.
Both transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on December 12, 2024. Additionally, Ceesay holds an indirect interest in 81,729 shares through The Ceesay Family Irrevocable Trust.
Rapport Therapeutics, a clinical-stage biotechnology company currently valued at approximately $1.26 billion, has experienced a remarkable 95.7% rise in stock price over the last twelve months. The company's focus remains on developing treatments for epilepsy, with recent regulatory advancements and strategic research developments strengthening its pipeline.
In a notable update, Rapport Therapeutics has accelerated its timeline to commence Phase 3 clinical trials of RAP-219, an investigational drug targeting epilepsy, now expected to begin in the second quarter of 2026. This advancement follows productive dialogues with the U.S. Food and Drug Administration, which has authorized progression to registrational trials. Further expanding its epilepsy portfolio, the company announced plans for a new program aimed at addressing primary generalized tonic-clonic seizures, with clinical studies anticipated to start within the first half of 2027.
The advancing clinical progress, underscored by encouraging Phase 2 trial outcomes, has drawn positive reactions from financial analysts. Citizen Securities reiterated a Market Outperform rating accompanied by an $80 price objective. Goldman Sachs also kept a Buy rating with a price target of $51, guided by robust Phase 2 data. Meanwhile, H.C. Wainwright upgraded its price target to $40 from $34, citing promising clinical results.
Data shared by Goldman Sachs highlights that RAP-219 demonstrated a 77.8% reduction in clinical seizures during Phase 2 trials, with nearly one-quarter of participants achieving complete seizure freedom. These findings were further substantiated through additional analyses disclosed at the American Epilepsy Society conference. Citizen Securities emphasized the significance of these new data points in maintaining their supportive stance on Rapport Therapeutics.